文献速递基础与转化研究新药、器械与细胞基因治疗研发

SGLT2抑制剂改善常见ALDH2酒精潮红变异相关的内皮功能障碍

SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant.
PubMed 文献 · Sci Transl Med · 2023-01-25

常见ALDH2*2酒精潮红变异影响全球约8%人口,与冠状动脉疾病(CAD)风险增加相关。研究通过日本生物样本库GWAS、携带者临床内皮功能评估、人诱导多能干细胞来源内皮细胞(iPSC-ECs)及CRISPR-Cas9校正模型、ALDH2*2敲入小鼠,发现ALDH2*2导致内皮功能障碍,恩格列净等SGLT2抑制剂可减轻该功能障碍,机制涉及抑制NHE-1并激活AKT/eNOS通路。

要点

  • ALDH2*2是CAD最强相关单核苷酸多态性之一。
  • 携带ALDH2*2者少量饮酒后血管舒张功能受损。
  • 恩格列净减轻ALDH2*2相关内皮功能障碍及小鼠血管功能障碍。

核心结论

  • ALDH2*2诱导内皮细胞功能障碍,SGLT2i或可作为ALDH2*2携带者预防CAD的潜在措施。

研究设计与样本

  • 研究整合日本生物样本库大规模全基因组关联研究、携带者临床内皮功能评估、人诱导多能干细胞来源内皮细胞(iPSC-ECs)及CRISPR-Cas9校正的ALDH2*2 iPSC-ECs体外模型、ALDH2*2敲入小鼠体内实验。

主要发现

  • 在日本生物样本库GWAS中,ALDH2*2是与CAD相关的最强单核苷酸多态性之一。
  • 携带ALDH2*2的人参与者少量饮酒后血管舒张功能受损。
  • ALDH2*2 iPSC-ECs显示氧化应激和炎症标志物增加、一氧化氮(NO)生成和成管能力下降,乙醇暴露进一步加重。
  • 恩格列净等SGLT2i减轻ALDH2*2相关内皮细胞功能障碍。
  • 在ALDH2*2敲入小鼠中,恩格列净减轻ALDH2*2介导的血管功能障碍。

临床怎么用

  • 原文结论提示SGLT2i或可作为ALDH2*2携带者预防CAD的潜在措施,原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The common aldehyde dehydrogenase 2 (ALDH2) alcohol flushing variant known as ALDH2*2 affects ∼8% of the world's population. Even in heterozygous carriers, this missense variant leads to a severe loss of ALDH2 enzymatic activity and has been linked to an increased risk of coronary artery disease (CAD). Endothelial cell (EC) dysfunction plays a determining role in all stages of CAD pathogenesis, including early-onset CAD. However, the contribution of ALDH2*2 to EC dysfunction and its relation to CAD are not fully understood. In a large genome-wide association study (GWAS) from Biobank Japan, ALDH2*2 was found to be one of the strongest single-nucleotide polymorphisms associated with CAD. Clinical assessment of endothelial function showed that human participants carrying ALDH2*2 exhibited impaired vasodilation after light alcohol drinking. Using human induced pluripotent stem cell-derived ECs (iPSC-ECs) and CRISPR-Cas9-corrected ALDH2*2 iPSC-ECs, we modeled ALDH2*2-induced EC dysfunction in vitro, demonstrating an increase in oxidative stress and inflammatory markers and a decrease in nitric oxide (NO) production and tube formation capacity, which was further exacerbated by ethanol exposure. We subsequently found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin mitigated ALDH2*2-associated EC dysfunction. Studies in ALDH2*2 knock-in mice further demonstrated that empagliflozin attenuated ALDH2*2-mediated vascular dysfunction in vivo. Mechanistically, empagliflozin inhibited Na+/H+-exchanger 1 (NHE-1) and activated AKT kinase and endothelial NO synthase (eNOS) pathways to ameliorate ALDH2*2-induced EC dysfunction. Together, our results suggest that ALDH2*2 induces EC dysfunction and that SGLT2i may potentially be used as a preventative measure against CAD for ALDH2*2 carriers.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Guo H, Yu X, Liu Y, et al. SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant. Sci Transl Med. 2023. PMID: 36696485. doi:10.1126/scitranslmed.abp9952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。